Alteon starts ALT-711 Phase II

ALT began a U.S. Phase II trial of its ALT-711 in 25 patients with systolic hypertension. After a three-week placebo run-in period, patients will receive ALT-711 twice daily for 8 weeks. The primary endpoint of the trial is improvement in endothelial function as measured by vessel relaxation and biomarkers of endothelial function. ...